1. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the assessment of the safety of a new thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction
- Author
-
Peter Sinnaeve, John H. Alexander, Rafael Diaz, Alec Vahanian, Ann Belmans, Michal Tendera, Lars Wallentin, Frans Van de Werf, Christopher B. Granger, Kris Bogaerts, Paul W. Armstrong, Leopoldo Soares-Piegas, and Jennifer Adgey
- Subjects
Male ,medicine.medical_specialty ,Abciximab ,Injections, Subcutaneous ,Myocardial Infarction ,Tenecteplase ,Tissue plasminogen activator ,Drug Administration Schedule ,Immunoglobulin Fab Fragments ,Reperfusion therapy ,Fibrinolytic Agents ,Internal medicine ,medicine ,Humans ,Myocardial infarction ,Enoxaparin ,Infusions, Intravenous ,Aged ,Aged, 80 and over ,Aspirin ,Heparin ,business.industry ,Antibodies, Monoclonal ,Middle Aged ,medicine.disease ,Surgery ,Survival Rate ,Tissue Plasminogen Activator ,Injections, Intravenous ,Cardiology ,Drug Therapy, Combination ,Female ,Anterior Wall Myocardial Infarction ,Cardiology and Cardiovascular Medicine ,business ,Fibrinolytic agent ,Follow-Up Studies ,medicine.drug - Abstract
Background In the ASsessment of the Safety of a New Thrombolytic 3 (ASSENT-3) study, full-dose tenecteplase plus enoxaparin or half-dose tenecteplase plus abciximab reduced the frequency of ischemic complications of acute myocardial infarction, when compared to full-dose tenecteplase plus unfractionated heparin. The aim of the present study was to determine the effect of these fibrinolytic regimens on 1-year mortality. Methods and results Vital status at 1 year was available for 5942 patients (97.5%) of the 6095 initially enrolled in the study. At 1 year, 515 patients (8.7%) had died. Elderly or female patients and patients with low body weight, previous myocardial infarction, anterior wall myocardial infarction, and diabetes were at increased risk for death at 1 year. Mortality at 1 year was 7.9 % (n = 161) in the heparin group, 8.1% (n = 166) in the enoxaparin group, and 9.3% (n = 188) in the abciximab group ( P = .226). Overall, pairwise comparisons did not show a significant difference among treatment regimens: relative risk 1.03 (95% CI 0.82–1.30) for enoxaparin versus heparin ( P = .794) and relative risk 1.18 (95% CI 0.95–1.47) for abciximab versus heparin ( P = .144). However, 1-year outcome tended to be worse with abciximab in diabetic patients. Conclusion Mortality at 1 year after acute myocardial infarction remains high. Despite a reduction in ischemic complications after acute myocardial infarction with the use of full-dose tenecteplase plus enoxaparin or half-dose tenecteplase plus abciximab, mortality at 1 year was similar in these treatment groups.
- Published
- 2004
- Full Text
- View/download PDF